Importance of collection tube during clinical studies of oseltamivir

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1835-1836

  Lindegardh, Niklas ^a,b,e   Davies, Geraint R ^a,c   Tran, Tinh Hien ^d   Farrar, Jeremy ^b,d   Singhasivanon, Pratap ^a   Day, Nicholas P J ^a,b   White, Nicholas J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLORVOS; DRUG METABOLITE; ESTERASE INHIBITOR; FLUORIDE; OSELTAMIVIR; OXALIC ACID;

ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; EX VIVO STUDY; HEAT; HUMAN; INCUBATION TEMPERATURE; INCUBATION TIME; PLASMA; PRIORITY JOURNAL; TUBE; VIRUS INACTIVATION;

ANTIVIRAL AGENTS; BLOOD SPECIMEN COLLECTION; DRUG STABILITY; HUMANS; OSELTAMIVIR; TEMPERATURE;

EID: 34248381197     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01534-06     Document Type: Article

References (12)

1. Anonymous. 2001. Guidance for industry bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD.
2. de Jong, M. D., T. T. Tran, H. K. Truong, M. H. Vo, G. J. Smith, V. C. Nguyen, V. C. Bach, T. Q. Phan, Q. H. Do, Y. Guan, J. S. Peiris, T. H. Tran, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
3. He, G., J. Massarella, and P. Ward. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484.
4. Jefferson, T., V. Demicheli, D. Rivetti, M. Jones, C. DiPietrontoj, and A. Rivetti. 2006. Antivirals for influenza in healthy adults: systematic review. Lancet 367:303-313.
5. Lindegardh, N., G. R. Davies, T. H. Tran, J. Farrar, P. Singhasivanon, N. P. Day, and N. J. White. 2006. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob. Agents Chemother. 50:3197-3199.
6. Martin, L. S., J. S. McDougal, and S. L. Loskoski. 1985. Disinfection and inactivation of the human T lymphotropic virus type III/lymphadenopathy-associated virus. J. Infect. Dis. 152:400-403.
7. Monto, A. S. 2006. Vaccines and antiviral drugs in pandemic preparedness. Emerg. Infect. Dis. 12:55-60.
8. Oo, C., J. Barrett, G. Hill, J. Mann, A. Dorr, R. Dutkowski, and P. Ward. 2001. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr. Drugs 3:229-236.
9. Spire, B., D. Dormont, F. Barre-Sinoussi, L. Montagnier, and J. C. Chermann. 1985. Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet i:188-189.
10. Swayne, D. E., and J. R. Beck. 2004. Heat inactivation of avian influenza and Newcastle disease viruses in egg products. Avian Pathol. 33:512-518.
11. Ward, P., I. Small, J. Smith, P. Suter, and R. Dutkowski. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. I):i5-i21.
12. Wiltshire, H., B. Wiltshire, A. Citron, T. Clarke, C. Serpe, D. Gray, and W. Herron. 2000. Development of a high-performance liquid chromatographic mass spectrometric assay for the specific and sensitive quantitation of Ro 64-0802, an anti-influenza drug and its pro-drug, oseltamivir in human and animal plasma and urine. J. Chromatogr. B 745:373-388.